Nuclear receptors expression chart in peripheral blood mononuclear cells identifies patients with Metabolic Syndrome

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 12, 2013, Pages 2289-2301

  D'Amore, Simona ^a,b,c   Vacca, Michele ^a,c,d   Graziano, Giusi ^b,c   D'Orazio, Andria ^c   Cariello, Marica ^b,c   Martelli, Nicola ^c   Di Tullio, Giuseppe ^c   Salvia, Roberto ^a   Grandaliano, Giuseppe ^e   Belfiore, Anna ^a   Pellegrini, Fabio ^f   Palasciano, Giuseppe ^a   Moschetta, Antonio ^b  

^a UNIVERSITY OF BARI   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c Laboratory of Lipid Metabolism and Cancer   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

^e UNIVERSITY OF FOGGIA   (Italy)

^f Santa Maria Imbaro ^*  (Italy)

Author keywords

Epidemiology; Gene expression; Inflammation; Metabolic Syndrome; Nuclear receptors

Indexed keywords

CD14 ANTIGEN; CELL NUCLEUS RECEPTOR; MESSENGER RNA; NUCLEAR RECEPTOR NR1D1; NUCLEAR RECEPTOR NR4A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; MALE; METABOLIC SYNDROME X; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

EID: 84884967715     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.09.006     Document Type: Article

References (73)

1. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
2. Vacca M., Degirolamo C., Mariani-Costantini R., Palasciano G., Moschetta A. Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. Wiley Interdiscip. Rev. Syst. Biol. Med. 2011, 3:562-587.
3. LoSasso G., Murzilli S., Salvatore L., D'Errico I., Petruzzelli M., Conca P., Jiang Z.Y., Calabresi L., Parini P., Moschetta A. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab. 2010, 12:187-193.
4. Shulman A.I., Mangelsdorf D.J. Retinoid x receptor heterodimers in the metabolic syndrome. N. Engl. J. Med. 2005, 353:604-615.
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
6. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
7. Libby P. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2045-2051.
8. Linsel-Nitschke P., Tall A.R. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug Discov. 2005, 4:193-205.
9. Rader D.J. Regulation of reverse cholesterol transport and clinical implications. Am. J. Cardiol. 2003, 92:42J-49J.
10. Klucken J., Buchler C., Orso E., Kaminski W.E., Porsch-Ozcurumez M., Liebisch G., Kapinsky M., Diederich W., Drobnik W., Dean M., Allikmets R., Schmitz G. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:817-822.
11. Oram J.F., Vaughan A.M. ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins. Curr. Opin. Lipidol. 2000, 11:253-260.
12. Wang N., Lan D., Chen W., Matsuura F., Tall A.R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9774-9779.
13. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
14. Solt L.A., Wang Y., Banerjee S., Hughes T., Kojetin D.J., Lundasen T., Shin Y., Liu J., Cameron M.D., Noel R., Yoo S.H., Takahashi J.S., Butler A.A., Kamenecka T.M., Burris T.P. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature 2012, 485:62-68.
15. Yang X., Downes M., Yu R.T., Bookout A.L., He W., Straume M., Mangelsdorf D.J., Evans R.M. Nuclear receptor expression links the circadian clock to metabolism. Cell 2006, 126:801-810.
16. Costet P., Lalanne F., Gerbod-Giannone M.C., Molina J.R., Fu X., Lund E.G., Gudas L.J., Tall A.R. Retinoic acid receptor-mediated induction of ABCA1 in macrophages. Mol. Cell. Biol. 2003, 23:7756-7766.
17. Maitra U., Parks J.S., Li L. An innate immunity signaling process suppresses macrophage ABCA1 expression through IRAK-1-mediated downregulation of retinoic acid receptor alpha and NFATc2. Mol. Cell. Biol. 2009, 29:5989-5997.
18. Deluca H.F., Cantorna M.T. Vitamin D: its role and uses in immunology. FASEB J. 2001, 15:2579-2585.
19. Pilz S., Tomaschitz A., Marz W., Drechsler C., Ritz E., Zittermann A., Cavalier E., Pieber T.R., Lappe J.M., Grant W.B., Holick M.F., Dekker J.M. Vitamin D, cardiovascular disease and mortality. Clin. Endocrinol. (Oxf.) 2011, 75:575-584.
20. Szeto F.L., Reardon C.A., Yoon D., Wang Y., Wong K.E., Chen Y., Kong J., Liu S.Q., Thadhani R., Getz G.S., Li Y.C. Vitamin D receptor signaling inhibits atherosclerosis in mice. Mol. Endocrinol. 2012, 26:1091-1101.
21. Bonta P.I., van Tiel C.M., Vos M., Pols T.W., van Thienen J.V., Ferreira V., Arkenbout E.K., Seppen J., Spek C.A., van der Poll T., Pannekoek H., de Vries C.J. Nuclear receptors Nur77, Nurr1, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2288-2294.
22. Chao L.C., Wroblewski K., Zhang Z., Pei L., Vergnes L., Ilkayeva O.R., Ding S.Y., Reue K., Watt M.J., Newgard C.B., Pilch P.F., Hevener A.L., Tontonoz P. Insulin resistance and altered systemic glucose metabolism in mice lacking Nur77. Diabetes 2009, 58:2788-2796.
23. Pols T.W., Bonta P.I., de Vries C.J. NR4A nuclear orphan receptors: protective in vascular disease?. Curr. Opin. Lipidol. 2007, 18:515-520.
24. Brown J.D., Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007, 115:518-533.
25. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
26. Chinetti G., Gbaguidi F.G., Griglio S., Mallat Z., Antonucci M., Poulain P., Chapman J., Fruchart J.C., Tedgui A., Najib-Fruchart J., Staels B. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000, 101:2411-2417.
27. Chinetti-Gbaguidi G., Rigamonti E., Helin L., Mutka A.L., Lepore M., Fruchart J.C., Clavey V., Ikonen E., Lestavel S., Staels B. Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages. J. Lipid Res. 2005, 46:2717-2725.
28. Marx N., Duez H., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 2004, 94:1168-1178.
29. Kammerer I., Ringseis R., Biemann R., Wen G., Eder K. 13-hydroxy linoleic acid increases expression of the cholesterol transporters ABCA1, ABCG1 and SR-BI and stimulates apoA-I-dependent cholesterol efflux in RAW264.7 macrophages. Lipids Health Dis. 2011, 10:222.
30. Ozasa H., Ayaori M., Iizuka M., Terao Y., Uto-Kondo H., Yakushiji E., Takiguchi S., Nakaya K., Hisada T., Uehara Y., Ogura M., Sasaki M., Komatsu T., Horii S., Mochizuki S., Yoshimura M., Ikewaki K. Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARgamma/LXRalpha pathway: findings from in vitro and ex vivo studies. Atherosclerosis 2011, 219:141-150.
31. Robinson E., Grieve D.J. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol. Ther. 2009, 122:246-263.
32. Barish G.D., Atkins A.R., Downes M., Olson P., Chong L.W., Nelson M., Zou Y., Hwang H., Kang H., Curtiss L., Evans R.M., Lee C.H. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4271-4276.
33. Pei L., Castrillo A., Chen M., Hoffmann A., Tontonoz P. Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. J. Biol. Chem. 2005, 280:29256-29262.
34. Ayaori M., Yakushiji E., Ogura M., Nakaya K., Hisada T., Uto-Kondo H., Takiguchi S., Terao Y., Sasaki M., Komatsu T., Iizuka M., Yogo M., Uehara Y., Kagechika H., Nakanishi T., Ikewaki K. Retinoic acid receptor agonists regulate expression of ATP-binding cassette transporter G1 in macrophages. Biochim. Biophys. Acta 2012, 1821:561-572.
35. Mesko B., Poliska S., Szegedi A., Szekanecz Z., Palatka K., Papp M., Nagy L. Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. BMC Med. Genomics 2010, 3:15.
36. Palmieri L., Panico S., Vanuzzo D., Ferrario M., Pilotto L., Sega R., Cesana G., Giampaoli S. Evaluation of the global cardiovascular absolute risk: the Progetto CUORE individual score. Ann Ist. Super. Sanita 2004, 40:393-399.
37. D'Agostino R.B., Vasan R.S., Pencina M.J., Wolf P.A., Cobain M., Massaro J.M., Kannel W.B. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117:743-753.
38. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
39. Boyum A. Isolation of leucocytes from human blood. A two-phase system for removal of red cells with methylcellulose as erythrocyte-aggregating agent. Scand. J. Clin. Lab. Invest. Suppl. 1968, 97:9-29.
40. Cariello M., Simone S., Loverre A., Gigante M., Incampo F., Pietanza S., Colucci M., Schena F.P., Gesualdo L., Grandaliano G., Pertosa G. Coagulation activation is associated with nicotinamide adenine dinucleotide phosphate oxidase-dependent reactive oxygen species generation in hemodialysis patients. Antioxid. Redox Signal. 2012, 16:428-439.
41. Modica S., Gofflot F., Murzilli S., D'Orazio A., Salvatore L., Pellegrini F., Nicolucci A., Tognoni G., Copetti M., Valanzano R., Veschi S., Mariani-Costantini R., Palasciano G., Schoonjans K., Auwerx J., Moschetta A. The intestinal nuclear receptor signature with epithelial localization patterns and expression modulation in tumors. Gastroenterology 2010, 138:636-648.
42. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
43. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
44. Bookout A.L., Jeong Y., Downes M., Yu R.T., Evans R.M., Mangelsdorf D.J. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006, 126:789-799.
45. De Berardis G., Lucisano G., D'Ettorre A., Pellegrini F., Lepore V., Tognoni G., Nicolucci A. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012, 307:2286-2294.
46. Breiman L. Random forests. Mach. Learn. 2001, 45:5-32.
47. Diaz-Uriarte R., Alvarez de A.S. Gene selection and classification of microarray data using random forest. BMC Bioinforma. 2006, 7:3.
48. Liu Q., Sung A.H., Chen Z., Liu J., Chen L., Qiao M., Wang Z., Huang X., Deng Y. Gene selection and classification for cancer microarray data based on machine learning and similarity measures. BMC Genomics 2011, 12(Suppl. 5):S1.
49. Strobl C., Boulesteix A.L., Zeileis A., Hothorn T. Bias in random forest variable importance measures: illustrations, sources and a solution. BMC Bioinforma. 2007, 8:25.
50. Strobl C., Boulesteix A.L., Kneib T., Augustin T., Zeileis A. Conditional variable importance for random forests. BMC Bioinforma. 2008, 9:307.
51. Zhao Y., Howatt D.A., Gizard F., Nomiyama T., Findeisen H.M., Heywood E.B., Jones K.L., Conneely O.M., Daugherty A., Bruemmer D. Deficiency of the NR4A orphan nuclear receptor NOR1 decreases monocyte adhesion and atherosclerosis. Circ. Res. 2010, 107:501-511.
52. Rigamonti E., Chinetti-Gbaguidi G., Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1050-1059.
53. Valledor A.F., Ricote M. Nuclear receptor signaling in macrophages. Biochem. Pharmacol. 2004, 67:201-212.
54. Huang W., Glass C.K. Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1542-1549.
55. Hong C., Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr. Opin. Genet. Dev. 2008, 18:461-467.
56. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., Liao D., Nagy L., Edwards P.A., Curtiss L.K., Evans R.M., Tontonoz P. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 2001, 7:161-171.
57. Rigamonti E., Helin L., Lestavel S., Mutka A.L., Lepore M., Fontaine C., Bouhlel M.A., Bultel S., Fruchart J.C., Ikonen E., Clavey V., Staels B., Chinetti-Gbaguidi G. Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circ. Res. 2005, 97:682-689.
58. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005, 366:1059-1062.
59. Oh D.Y., Morinaga H., Talukdar S., Bae E.J., Olefsky J.M. Increased macrophage migration into adipose tissue in obese mice. Diabetes 2012, 61:346-354.
60. Sabol S.L., Brewer H.B., Santamarina-Fojo S. The human ABCG1 gene: identification of LXR response elements that modulate expression in macrophages and liver. J. Lipid Res. 2005, 46:2151-2167.
61. Huang J.T., Welch J.S., Ricote M., Binder C.J., Willson T.M., Kelly C., Witztum J.L., Funk C.D., Conrad D., Glass C.K. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999, 400:378-382.
62. Takata Y., Liu J., Yin F., Collins A.R., Lyon C.J., Lee C.H., Atkins A.R., Downes M., Barish G.D., Evans R.M., Hsueh W.A., Tangirala R.K. PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4277-4282.
63. Kang K., Reilly S.M., Karabacak V., Gangl M.R., Fitzgerald K., Hatano B., Lee C.H. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 2008, 7:485-495.
64. Shah A., Rader D.J., Millar J.S. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 2010, 210:35-40.
65. Steiner G. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. Am. J. Cardiol. 2008, 102:28L-33L.
66. Skogsberg J., Kannisto K., Cassel T.N., Hamsten A., Eriksson P., Ehrenborg E. Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler. Thromb. Vasc. Biol. 2003, 23:637-643.
67. Haghpassand M., Bourassa P.A., Francone O.L., Aiello R.J. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J. Clin. Invest. 2001, 108:1315-1320.
68. Altucci L., Leibowitz M.D., Ogilvie K.M., de Lera A.R., Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 2007, 6:793-810.
69. Schote A.B., Turner J.D., Schiltz J., Muller C.P. Nuclear receptors in human immune cells: expression and correlations. Mol. Immunol. 2007, 44:1436-1445.
70. Chao L., Soto E., Hong C., Ito A., Pei L., Chawla A., Conneely O., Tangirala R.K., Evans R.M., Tontonoz P. Bone marrow NR4A expression is not a dominant factor in the development of atherosclerosis or macrophage polarization in mice. J. Lipid Res. 2013, 54:806-815.
71. Adorini L., Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 2008, 4:404-412.
72. Staels B. When the clock stops ticking, metabolic syndrome explodes. Nat. Med. 2006, 12:54-55.
73. Wang J., Yin L., Lazar M.A. The orphan nuclear receptor Rev-erb alpha regulates circadian expression of plasminogen activator inhibitor type 1. J. Biol. Chem. 2006, 281:33842-33848.